| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.
|
Circulation
|
2010
|
5.87
|
|
2
|
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.
|
Circulation
|
2005
|
2.98
|
|
3
|
Pulmonary arterial hypertension in patients treated by dasatinib.
|
Circulation
|
2012
|
2.87
|
|
4
|
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
|
Eur Heart J
|
2006
|
2.34
|
|
5
|
Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry.
|
Circulation
|
2011
|
1.92
|
|
6
|
Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases.
|
Anesthesiology
|
2005
|
1.88
|
|
7
|
Portopulmonary hypertension: survival and prognostic factors.
|
Am J Respir Crit Care Med
|
2008
|
1.71
|
|
8
|
Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies.
|
Chest
|
2012
|
1.68
|
|
9
|
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
|
Am J Respir Crit Care Med
|
2010
|
1.50
|
|
10
|
Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis.
|
Chest
|
2010
|
1.48
|
|
11
|
Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.
|
Medicine (Baltimore)
|
2008
|
1.43
|
|
12
|
Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.
|
Chest
|
2013
|
1.39
|
|
13
|
Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.
|
Chest
|
2006
|
1.29
|
|
14
|
HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era.
|
AIDS
|
2010
|
1.27
|
|
15
|
Pulmonary arterial hypertension.
|
Orphanet J Rare Dis
|
2013
|
1.18
|
|
16
|
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
|
Adv Ther
|
2009
|
1.10
|
|
17
|
Treatment of pulmonary arterial hypertension with targeted therapies.
|
Nat Rev Cardiol
|
2011
|
1.08
|
|
18
|
Pulmonary veno-occlusive disease: recent progress and current challenges.
|
Respir Med
|
2010
|
1.06
|
|
19
|
Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction.
|
Respiration
|
2012
|
1.03
|
|
20
|
POEMS syndrome-related pulmonary hypertension is steroid-responsive.
|
Respir Med
|
2006
|
1.02
|
|
21
|
High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms.
|
Chest
|
2013
|
1.02
|
|
22
|
Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.
|
Eur Heart J
|
2010
|
1.01
|
|
23
|
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey.
|
Eur Respir J
|
2012
|
0.96
|
|
24
|
Pulmonary hypertension in patients with neurofibromatosis type I.
|
Medicine (Baltimore)
|
2011
|
0.90
|
|
25
|
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
|
J Heart Lung Transplant
|
2011
|
0.90
|
|
26
|
Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.
|
Proc Am Thorac Soc
|
2006
|
0.90
|
|
27
|
Therapeutic advances in pulmonary arterial hypertension.
|
Ther Adv Respir Dis
|
2008
|
0.88
|
|
28
|
Pulmonary hypertension associated with benfluorex exposure.
|
Eur Respir J
|
2012
|
0.85
|
|
29
|
Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients.
|
Eur Respir J
|
2012
|
0.85
|
|
30
|
EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism.
|
Eur Respir J
|
2012
|
0.85
|
|
31
|
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2.
|
Chest
|
2015
|
0.85
|
|
32
|
Idiopathic pulmonary hypertension: what did we learn from genes?
|
Sarcoidosis Vasc Diffuse Lung Dis
|
2005
|
0.84
|
|
33
|
Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension.
|
Respir Med
|
2010
|
0.84
|
|
34
|
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.
|
Eur Respir J
|
2012
|
0.83
|
|
35
|
Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.
|
Expert Opin Pharmacother
|
2011
|
0.82
|
|
36
|
[Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis].
|
Presse Med
|
2009
|
0.80
|
|
37
|
Mediastinal fibrosis mimicking proximal chronic thromboembolic disease.
|
Circulation
|
2012
|
0.78
|
|
38
|
[Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension].
|
Rev Prat
|
2008
|
0.78
|
|
39
|
Pulmonary Hypertension Complicating Fibrosing Mediastinitis.
|
Medicine (Baltimore)
|
2015
|
0.78
|
|
40
|
Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?
|
Presse Med
|
2011
|
0.77
|
|
41
|
Ventilation/perfusion lung scan in pulmonary veno-occlusive disease.
|
Eur Respir J
|
2011
|
0.76
|
|
42
|
[Contraception, therapeutic abortion, and pulmonary arterial hypertension].
|
Presse Med
|
2010
|
0.75
|
|
43
|
Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.
|
Am J Cardiovasc Drugs
|
2015
|
0.75
|
|
44
|
[Treatment of pulmonary arterial hypertension in 2011: what's new since the 2009 ERS/ESC guidelines?].
|
Presse Med
|
2011
|
0.75
|